Stock Chart
PHAT
Type: SELL wallstreet
Strike: $23
Premium: $1.77
Expiry: Jan 15, 2027
Target: $24
Score: -44
LEAPs are long-term options (1+ year) with less time decay.
Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech
Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity
Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
About PHAT - Phathom Pharmaceuticals, Inc. Common Stock
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Key Statistics
More PHAT Analysis
This PHAT stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track PHAT's price movements with trendlines, gamma walls, and key support/resistance levels.